Tyrosine kinase inhibitors (TKI): others
Evidence-based neurology checklist on tyrosine kinase inhibitors (tki): others: Ponatinib complications Myelosuppression Hepatotoxicity Pancreatitis Arterial thrombosis Pityriasis rubra pilaris-like lesions Ichthyosiform eruptions Facial erythema Arterial thrombosis Hypertension Regorafenib…
Ponatinib complications
- Myelosuppression
- Hepatotoxicity
- Pancreatitis
- Arterial thrombosis
- Pityriasis rubra pilaris-like lesions
- Ichthyosiform eruptions
- Facial erythema
- Arterial thrombosis
- Hypertension
Regorafenib complications
Bosutinib complications
Sorafenib complications
Other TKIs causing posterior reversible encephalopathy syndrome (PRES)
Other TKIs causing myasthenia gravis
TKIs causing QTc interval prolongation
Other TKI complications
References
- Shamroe CL, Comeau JM. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Ann Pharmacother 2013; 47:1540-1546.
- Eber AE, Rosen A, Oberlin KE, Giubellino A, Romanelli P. Ichthyosiform pityriasis rubra pilaris-like eruption secondary to ponatinib therapy: case report and literature review. Drug Saf Case Rep 2017; 4:19.
- Krygier J, Leemans G, Forsyth R, de Becker A, Gutermuth J, Grosber M. A new case of pityriasis rubra pilaris-like eruption associated with ponatinib, a tyrosine kinase inhibitor. Ann Dermatol Venereol 2018; 145:665-670.
- Munera-Campos M, Carrascosa JM, Quer A, Ferrándiz C. Ichthyosiform eruption and facial erythema secondary to ponatinib therapy. J Dtsch Dermatol Ges 2020; 18:743-747.
- Haguet H, Bouvy C, Delvigne AS, et al. The risk of arterial thrombosis in patients with chronic myeloid leukemia treated with second and third generation BCR-ABL tyrosine kinase inhibitors may be explained by their impact on endothelial cells: an in-vitro study. Front Pharmacol 2020; 11:1007.
- And 28 more. Subscribe to see the full list
